Ahmedabad, Gujarat, India, September 2025 — Amul Agrawal has been appointed as Chief Strategy Officer (CSO) at Torrent Pharmaceuticals Ltd, a pivotal leadership role that will see him drive corporate strategy, global growth, and M&A initiatives across key geographies.
Amul has been with Torrent Pharmaceuticals Ltd for over 14 years, most recently serving as Global Head of Portfolio and M&A while also holding the position of President – Europe. Based in Germany, he successfully steered Torrent’s European business operations, strengthening the company’s market position and leading cross-border acquisitions that expanded Torrent’s global footprint.
Before this, Amul was Managing Director at Heumann Pharma GmbH & Co. Generica KG, where he played a central role in strategic transformation and growth, after initially serving as the organization’s Chief Operating Officer. His leadership at Heumann enhanced business development and operational efficiency, positioning the company as a strong player in the German generics market.
Earlier in his career, Amul held progressive roles within Torrent Pharma GmbH as Director of Strategy and Business Development and Head of Business Development, where he led expansion strategies in the European market. He began his professional journey with Torrent Pharmaceuticals Ltd in India as a Business Development Manager, building expertise in portfolio strategy and international business growth.
Amul also contributed early in his career as Head of PnP at AIESEC, where he developed skills in leadership and cross-cultural collaboration. He holds an MBA from B.K. School of Professional and Management Studies, which provided the academic foundation for his global leadership journey.
About Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd is the flagship company of the Torrent Group, with annual revenues exceeding Rs 10,700 crores and group revenues of Rs 41,000 crores. Ranked 5th in the Indian Pharma Market, Torrent is a leader in cardiovascular, central nervous system, gastro-intestinal, vitamins-minerals-nutritionals, and cosmo-dermatology segments. It also has a significant presence in diabetology, oncology, gynaecology, pain management, and anti-infectives.
Torrent operates eight manufacturing facilities, including five USFDA-approved plants, and employs around 800 scientists in its state-of-the-art R&D infrastructure. With a presence in over 50 countries, Torrent is ranked No. 1 among Indian pharma companies in Brazil and Germany, solidifying its global standing through strategic acquisitions and strong portfolio growth.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
